Current View of the Budd-Chiari Syndrome Clinical Approach |Biomedgrid

The Budd-Chiari Syndrome (SBC) was first mentioned in 1845 by George Budd, a British physician who associated liver thrombosis with liver abscess, and then in 1899 by Hans Chiari, an Austrian pathologist, who delimited a clinical and pathological condition relating to the disease of primary obliterative endophlebitis. The disease became known as Budd-Chiari syndrome [1-3]. The Budd-Chiari syndrome is a rare disease in which obstruction of the hepatic veins occurs, which can be thrombotic or non-thrombotic, thus leads to a progressive centrilobular liver retention, resulting in cirrhosis [1,4]. This thrombus can occur anywhere in the venous pathway, from the hepatic venules to the junction of the inferior vena cava to the right atrium [1]. The causes that determine SBC include coagulation abnormality, trauma, tumor extension (neoplasia) or obstructive congenital abnormalities (thrombophilia) [3].